The trial met both primary endpoints, with tirzepatide showing a 38% decrease in heart failure outcomes compared to placebo.

Tirzepatide is a long-acting dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist.

In the international SUMMIT trial, adults with heart failure preserved ejection fraction (HFpEF) and obesity taking ...

Tirzepatide, currently marketed by Eli Lilly (NYSE:LLY) as Mounjaro and Zepbound for diabetes and weight loss, respectively, ...

The FDA’s decision to allow the compounding of GLP-1 weight loss drugs could undermine its public health obligations, writes ...

Popular anti-obesity drugs continue to show cardiovascular benefits beyond weight loss, according to several new papers ...

HF specialists agree these drugs will be key tools in fighting the obesity-related HFpEF epidemic. Hurdles and questions ...

"Obesity contributes to worsening heart failure, and while tirzepatide causes considerable weight loss, research is lacking ...

The Company is seeking approval of tirzepatide for the treatment of HFpEF and obesity and has submitted data to the FDA. Detailed results were announced from a phase 3 clinical trial evaluating the ...

Spanning 176 weeks of treatment, the Phase III trial evaluated the efficacy and safety of tirzepatide in adults without type ...

SUMMT has shown for the first time that a drug can reduce major heart failure clinical outcomes in patients with heart ...

For patients with obesity and prediabetes, three years of tirzepatide yields substantial and sustained weight reduction and a reduced risk for progression to type 2 diabetes, according to a study ...